Jefferies Financial Group lowered shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a buy rating to a hold rating in a report issued on Monday morning, BenzingaRatingsTable reports. Jefferies Financial Group also issued estimates for GALAPAGOS NV/S’s Q3 2019 earnings at ($1.80) EPS, Q4 2019 earnings at $8.10 EPS, FY2019 earnings at $5.30 EPS, FY2020 earnings at $0.40 EPS, FY2021 earnings at ($1.20) EPS, FY2022 earnings at $3.20 EPS and FY2023 earnings at $1.40 EPS.
GLPG has been the subject of a number of other reports. Credit Suisse Group reiterated an outperform rating on shares of GALAPAGOS NV/S in a research note on Wednesday, July 10th. BidaskClub upgraded GALAPAGOS NV/S from a buy rating to a strong-buy rating in a research note on Saturday, July 13th. Stifel Nicolaus lifted their price target on GALAPAGOS NV/S from $121.00 to $188.00 and gave the stock a buy rating in a research note on Monday, July 15th. Cantor Fitzgerald reiterated a buy rating and issued a $130.00 price target on shares of GALAPAGOS NV/S in a research note on Thursday, May 2nd. Finally, Raymond James downgraded GALAPAGOS NV/S from a strong-buy rating to a market perform rating in a research note on Monday, July 15th. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $156.45.
NASDAQ:GLPG opened at $174.23 on Monday. The firm has a market capitalization of $9.06 billion, a P/E ratio of -263.98 and a beta of 1.54. GALAPAGOS NV/S has a one year low of $85.00 and a one year high of $191.63. The stock has a 50-day moving average price of $148.13. The company has a quick ratio of 6.40, a current ratio of 6.40 and a debt-to-equity ratio of 0.02.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Featured Story: Does a trade war provide a risk to the global economy?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.